Citigroup
BLCM

Citigroup’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Citigroup’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-125
Closed – – 6086
2022
Q3 		$0 Buy
+125
New +$159 ﹤0.01% 6542
2022
Q2 		– Sell
-188
Closed – – 6832
2022
Q1 		$0 Buy
+188
New +$306 ﹤0.01% 6754
2020
Q1 		– Sell
-454
Closed -$6K – 7833
2019
Q4 		$6K Hold
454
– – ﹤0.01% 7366
2019
Q3 		$5K Sell
454
-1,651
-78% -$21.6K ﹤0.01% 7362
2019
Q2 		$36K Buy
2,105
+842
+67% +$22.8K ﹤0.01% 6746
2019
Q1 		$42K Sell
1,263
-15
-1% -$501 ﹤0.01% 6477
2018
Q4 		$37K Sell
1,278
-15
-1% -$665 ﹤0.01% 6481
2018
Q3 		$80K Sell
1,293
-1,698
-57% -$115K ﹤0.01% 6114
2018
Q2 		$221K Buy
2,991
+1,814
+154% +$141K ﹤0.01% 4969
2018
Q1 		$77K Buy
1,177
+1,154
+5,017% +$87.1K ﹤0.01% 5840
2017
Q4 		$2K Sell
23
-98
-81% -$9.61K ﹤0.01% 7417
2017
Q3 		$14K Buy
121
+103
+572% +$10.8K ﹤0.01% 6590
2017
Q2 		$2K Buy
18
+2
+13% +$248 ﹤0.01% 7049
2017
Q1 		$2K Buy
+16
New +$2.1K ﹤0.01% 7026
2016
Q4 		– Sell
-99
Closed -$20K – 7372
2016
Q3 		$20K Sell
99
-159
-62% -$27.4K ﹤0.01% 6221
2016
Q2 		$33K Sell
258
-389
-60% -$43.3K ﹤0.01% 5843
2016
Q1 		$60K Sell
647
-934
-59% -$102K ﹤0.01% 6003
2015
Q4 		$320K Buy
1,581
+398
+34% +$71.2K ﹤0.01% 4301
2015
Q3 		$172K Sell
1,183
-18
-1% -$3.3K ﹤0.01% 4625
2015
Q2 		$256K Sell
1,201
-983
-45% -$241K ﹤0.01% 4244
2015
Q1 		$507K Buy
+2,184
New +$528K ﹤0.01% 3732

Other funds holding BLCM

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Citigroup's BLCM Position: Q4 2022 in Review

Citigroup sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2022, closing a stake of 125 shares.

Citigroup first reported a position in BLCM in Q1 2015 and held it in 21 quarters. The position peaked at $507K in Q1 2015. 33 funds tracked by Wall St. Rank hold BLCM as of Q4 2022.

  • Citigroup reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Citigroup sold 125 Bellicum Pharmaceuticals, Inc. shares in Q4 2022.
  • Citigroup first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 21 quarters.
  • Citigroup's Bellicum Pharmaceuticals, Inc. position peaked at $507K in Q1 2015.
  • 33 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2022.

Based on Citigroup's 13F filing for Q4 2022, filed 9 Feb 2023.